Your browser doesn't support javascript.
loading
Clinical reasearch of bendamustine combination regimen in the treatment of relapsed/refractory multiple myeloma / 中国医师杂志
Journal of Chinese Physician ; (12): 1822-1827, 2021.
Article in Chinese | WPRIM | ID: wpr-932004
ABSTRACT

Objective:

To investigate the clinical efficacy and safety of bendamustine combination regimen in the treatment of patients with relapsed or refractory multiple myeloma (RRMM).

Methods:

From March 2020 to December 2020, 16 patients with RRMM were treated with bendamustine combination regimen in Beijing Jishuitan Hospital. The efficacy and adverse events (AEs) of bendamustine combination regimen were retrospectively analyzed in the 16 patients.

Results:

The median treatment lines for 16 patients with RRMM who received bendamustine combination regimen was 4 lines, and the median course of treatment was 3 (1-8). The median follow-up time after bendamustine treatment started was 5.3(1.3-9.2)months. Among the 16 cases, the disease control rate (DCR), overall response rate(ORR), and ≥ very good partial remission (VGPR) rate were 13/16, 5/16, 4/16 respectively. The median PFS was 4.9 months. Among them, the ORR of bendamustine combined with immunomodulators was higher. AEs were anemia, leukopenia, neutropenia, thrombocytopenia and fatigue. No patients who stopped treatment and adjusted the dose due to AEs.

Conclusions:

Bendamustine combination regimen is an effective and safe regimen for relapsed/refractory multiple myeloma.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Journal of Chinese Physician Year: 2021 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Journal of Chinese Physician Year: 2021 Type: Article